
Iqvia Holdings (IQV) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
3.8B
Gross Profit
1.3B
33.90%
Operating Income
525.0M
13.71%
Net Income
249.0M
6.50%
EPS (Diluted)
$1.40
Balance Sheet Metrics
Total Assets
27.3B
Total Liabilities
21.3B
Shareholders Equity
6.0B
Debt to Equity
3.57
Cash Flow Metrics
Operating Cash Flow
554.0M
Free Cash Flow
426.0M
Revenue & Profitability Trend
Iqvia Holdings Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 15.4B | 15.0B | 14.4B | 13.9B | 11.4B |
Cost of Goods Sold | 10.0B | 9.7B | 9.4B | 9.2B | 7.5B |
Gross Profit | 5.4B | 5.2B | 5.0B | 4.6B | 3.9B |
Gross Margin % | 34.9% | 35.0% | 34.9% | 33.5% | 34.0% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 2.0B | 2.1B | 2.1B | 2.0B | 1.8B |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 2.0B | 2.1B | 2.1B | 2.0B | 1.8B |
Operating Income | 2.3B | 2.1B | 1.8B | 1.4B | 783.0M |
Operating Margin % | 14.7% | 13.8% | 12.7% | 10.2% | 6.9% |
Non-Operating Items | |||||
Interest Income | 47.0M | 36.0M | 13.0M | 6.0M | 6.0M |
Interest Expense | 670.0M | 672.0M | 416.0M | 375.0M | 416.0M |
Other Non-Operating Income | 23.0M | 34.0M | -61.0M | 84.0M | - |
Pre-tax Income | 1.7B | 1.5B | 1.4B | 1.1B | 373.0M |
Income Tax | 301.0M | 101.0M | 260.0M | 163.0M | 72.0M |
Effective Tax Rate % | 18.0% | 6.9% | 19.1% | 14.5% | 19.3% |
Net Income | 1.4B | 1.4B | 1.1B | 971.0M | 308.0M |
Net Margin % | 8.9% | 9.1% | 7.6% | 7.0% | 2.7% |
Key Metrics | |||||
EBITDA | 3.5B | 3.3B | 2.9B | 2.8B | 2.1B |
EPS (Basic) | $7.57 | $7.39 | $5.82 | $5.05 | $1.46 |
EPS (Diluted) | $7.49 | $7.29 | $5.72 | $4.95 | $1.43 |
Basic Shares Outstanding | 181300000 | 183800000 | 187600000 | 191400000 | 191300000 |
Diluted Shares Outstanding | 181300000 | 183800000 | 187600000 | 191400000 | 191300000 |
Income Statement Trend
Iqvia Holdings Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.7B | 1.4B | 1.2B | 1.4B | 1.8B |
Short-term Investments | 141.0M | 120.0M | 93.0M | 111.0M | 88.0M |
Accounts Receivable | 1.4B | 1.5B | 1.3B | 1.3B | 1.2B |
Inventory | - | - | - | - | - |
Other Current Assets | 592.0M | 546.0M | 561.0M | 521.0M | 563.0M |
Total Current Assets | 5.8B | 5.6B | 5.0B | 4.8B | 5.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.4B | 1.5B | 1.5B | 1.5B | 1.5B |
Goodwill | 33.9B | 34.0B | 32.7B | 31.5B | 30.5B |
Intangible Assets | 4.5B | 4.8B | 4.8B | 4.9B | 5.2B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 714.0M | 621.0M | 590.0M | 615.0M | 500.0M |
Total Non-Current Assets | 21.1B | 21.1B | 20.4B | 19.9B | 19.5B |
Total Assets | 26.9B | 26.7B | 25.3B | 24.7B | 24.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 736.0M | 709.0M | 645.0M | 621.0M | 581.0M |
Short-term Debt | 1.1B | 718.0M | 152.0M | 91.0M | 149.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 193.0M | 294.0M | 152.0M | 207.0M | 242.0M |
Total Current Liabilities | 7.0B | 6.5B | 5.6B | 5.2B | 4.6B |
Non-Current Liabilities | |||||
Long-term Debt | 13.0B | 13.2B | 12.9B | 12.3B | 12.8B |
Deferred Tax Liabilities | 196.0M | 202.0M | 464.0M | 410.0M | 338.0M |
Other Non-Current Liabilities | 668.0M | 698.0M | 671.0M | 649.0M | 633.0M |
Total Non-Current Liabilities | 13.9B | 14.1B | 14.0B | 13.4B | 13.7B |
Total Liabilities | 20.8B | 20.6B | 19.6B | 18.6B | 18.3B |
Equity | |||||
Common Stock | 3.0M | 11.0B | 10.9B | 3.0M | 11.1B |
Retained Earnings | 6.1B | 4.7B | 3.3B | 2.2B | 1.3B |
Treasury Stock | 10.1B | 8.7B | 7.7B | 6.6B | 6.2B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 6.1B | 6.1B | 5.8B | 6.0B | 6.3B |
Key Metrics | |||||
Total Debt | 14.2B | 13.9B | 13.0B | 12.4B | 12.9B |
Working Capital | -1.1B | -895.0M | -597.0M | -478.0M | 532.0M |
Balance Sheet Composition
Iqvia Holdings Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.4B | 1.4B | 1.1B | 971.0M | 308.0M |
Depreciation & Amortization | 1.1B | 1.1B | 1.1B | 1.3B | 1.3B |
Stock-Based Compensation | 206.0M | 217.0M | 194.0M | 170.0M | 95.0M |
Working Capital Changes | 306.0M | -150.0M | 37.0M | 697.0M | 688.0M |
Operating Cash Flow | 2.9B | 2.3B | 2.4B | 3.0B | 2.2B |
Investing Activities | |||||
Capital Expenditures | -577.0M | -649.0M | -674.0M | -640.0M | -616.0M |
Acquisitions | -867.0M | -915.0M | -1.3B | -1.5B | -167.0M |
Investment Purchases | -2.0M | -44.0M | -5.0M | -10.0M | -11.0M |
Investment Sales | - | - | 0 | 5.0M | - |
Investing Cash Flow | -1.4B | -1.6B | -2.0B | -2.1B | -796.0M |
Financing Activities | |||||
Share Repurchases | -1.4B | -992.0M | -1.2B | -406.0M | -447.0M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 1.7B | 4.0B | 1.2B | 2.0B | 1.6B |
Debt Repayment | -1.1B | -5.6B | -2.7B | -2.7B | -2.5B |
Financing Cash Flow | -814.0M | -3.0B | -2.3B | -1.8B | -1.8B |
Free Cash Flow | 2.1B | 1.5B | 1.6B | 2.3B | 1.3B |
Net Change in Cash | 633.0M | -2.3B | -1.9B | -898.0M | -384.0M |
Cash Flow Trend
Iqvia Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
27.69
Forward P/E
15.83
Price to Book
5.62
Price to Sales
2.07
PEG Ratio
-1.25
Profitability Ratios
Profit Margin
7.88%
Operating Margin
13.39%
Return on Equity
19.79%
Return on Assets
5.16%
Financial Health
Current Ratio
0.84
Debt to Equity
272.12
Beta
1.30
Per Share Data
EPS (TTM)
$6.90
Book Value per Share
$33.99
Revenue per Share
$88.63
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
iqv | 32.5B | 27.69 | 5.62 | 19.79% | 7.88% | 272.12 |
Thermo Fisher | 184.7B | 28.25 | 3.66 | 13.42% | 15.24% | 69.62 |
Danaher | 151.0B | 44.88 | 2.89 | 6.68% | 14.21% | 35.45 |
Idexx Laboratories | 52.1B | 54.06 | 35.76 | 64.87% | 24.41% | 84.81 |
Agilent Technologies | 33.9B | 29.36 | 5.52 | 18.88% | 17.59% | 60.04 |
Mettler-Toledo | 27.0B | 33.22 | - | -680.23% | 21.46% | -8.44 |
Financial data is updated regularly. All figures are in the company's reporting currency.